Ash 2021 preview – as competition grows Autolus monetises
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
What Novartis could buy with its windfall
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Triple meeting – low-profile assets boost Merus and Bicycle
Merus regains some lost pride while Bicycle rides to even greater heights.
J&J breathes some more life into plamotamab and CD28
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Non-genetic amyloidosis lives again, thanks to Darzalex and Astra
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
Incyte and Seagen face tricky launches
Black box warnings could limit the sales of their newly approved therapeutics.
